CANCER FACT SHEET 2023
MELANOMA
ICD-10 C43

Belgian Cancer Registry

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*(1.05)^5).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2023, obtained from Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

TABLE OF CONTENTS

Belgian Cancer Registry

Belgian Cancer Registry

1.1. Melanoma incidence: by region

1.1.1. Melanoma incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Males																						
Belgium	0	0	1	2	7	13	35	46	102	101	177	218	251	242	227	241	183	91	40	8	1,985	36.1
	[0.0]	[0.0]	[0.3]	[0.6]	[2.0]	[3.6]	[9.0]	[12.3]	[26.5]	[27.1]	[44.8]	[54.2]	[67.0]	[76.1]	[85.2]	[118.5]	[146.5]	[114.1]	[127.7]	[132.0]	[34.5]	(34.5; 37.7)
Brussels	0	0	0	0	0	1	2	1	9	2	16	13	12	16	13	14	13	5	2	0	119	28.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.0]	[3.8]	[2.1]	[19.5]	[4.5]	[39.1]	[36.7]	[41.6]	[74.9]	[77.3]	[110.9]	[161.6]	[99.9]	[86.8]	[0.0]	[19.6]	(23.2; 33.8)
Flanders	0	0	1	1	6	8	25	23	60	64	114	153	170	162	149	171	130	60	32	7	1,336	39.6
	[0.0]	[0.0]	[0.5]	[0.5]	[3.2]	[4.0]	[11.6]	[10.9]	[27.1]	[30.3]	[49.8]	[63.1]	[74.3]	[82.7]	[90.8]	[131.2]	[157.7]	[111.5]	[153.8]	[176.3]	[39.9]	(37.5; 41.7)
Wallonia	0	0	0	1	1	4	8	22	33	35	47	52	69	64	65	56	40	26	6	1	530	31.5
	[0.0]	[0.0]	[0.0]	[0.9]	[0.9]	[3.6]	[6.7]	[18.9]	[28.3]	[29.6]	[37.5]	[41.7]	[59.0]	[63.5]	[76.1]	[92.9]	[116.3]	[124.2]	[72.9]	[64.4]	[29.4]	(28.8; 34.2)
Females																						
Belgium	0	0	1	7	19	42	74	92	146	176	242	247	227	234	212	232	158	79	47	12	2,247	37.0
	[0.0]	[0.0]	[0.3]	[2.1]	[5.7]	[11.6]	[18.9]	[24.3]	[38.0]	[47.9]	[62.3]	[62.2]	[59.5]	[69.1]	[71.4]	[94.4]	[90.7]	[59.0]	[66.3]	[57.6]	[37.9]	(35.5; 38.6)
Brussels	0	0	0	0	1	4	1	1	7	13	13	14	13	11	17	21	4	6	3	0	129	24.9
	[0.0]	[0.0]	[0.0]	[0.0]	[2.4]	[7.2]	[1.8]	[2.1]	[15.3]	[31.6]	[34.0]	[41.1]	[43.0]	[44.0]	[79.3]	[116.6]	[31.1]	[61.2]	[52.9]	[0.0]	[20.4]	(20.6; 29.3)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	0	0	1	6	13	26	50	63	90	119	174	169	163	165	144	163	115	58	35	8	1,562	43.5
	[0.0]	[0.0]	[0.5]	[3.3]	[7.1]	[13.0]	[23.1]	[29.6]	[40.7]	[57.2]	[77.4]	[71.5]	[71.4]	[81.6]	[82.0]	[108.5]	[105.1]	[68.0]	[79.5]	[65.3]	[45.6]	(41.4; 45.7)
Wallonia	0	0	0	1	5	12	23	28	49	44	55	64	51	58	51	48	39	15	9	4	556	29.1
	[0.0]	[0.0]	[0.0]	[0.9]	[4.6]	[11.2]	[19.2]	[23.8]	[41.6]	[37.1]	[43.9]	[50.6]	[41.5]	[52.0]	[51.0]	[62.0]	[75.1]	[38.8]	[42.5]	[61.7]	[29.6]	(26.6; 31.5)

1.2. Melanoma incidence: by tumour stage

1.2.1. Melanoma incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-49	50-64	65+	All ages		15-49	50-64	65+	All ages	
I	248 [9.6]	532 [45.4]	710 [69.0]	1,490 [25.9]	26.8 (25.5; 28.2)	515 [20.2]	635 [54.4]	682 [53.2]	1,833 [30.9]	30.7 (29.3; 32.1)
II	37 [1.4]	84 [7.2]	225 [21.9]	347 [6.0]	6.5 (5.8; 7.2)	29 [1.1]	53 [4.5]	203 [15.8]	285 [4.8]	4.4 (3.8; 4.9)
III	9 [0.4]	6 [0.5]	23 [2.2]	38 [0.7]	0.7 (0.5; 0.9)	4 [0.2]	6 [0.5]	21 [1.6]	31 [0.5]	0.5 (0.3; 0.7)
IV	8 [0.3]	3 [0.3]	25 [2.4]	36 [0.6]	0.7 (0.5; 0.9)	3 [0.1]	6 [0.5]	20 [1.6]	29 [0.5]	0.4 (0.3; 0.6)
X/NA	4 [0.2]	21 [1.8]	49 [4.8]	74 [1.3]	1.4 (1.1; 1.7)	5 [0.2]	16 [1.4]	48 [3.7]	69 [1.2]	1.1 (0.8; 1.3)

1.2.2. Melanoma incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-49	50-64	65+	All ages		15-49	50-64	65+	All ages	
I	241 [9.4]	518 [44.2]	695 [67.5]	1,454 [25.2]	26.2 (24.8; 27.5)	505 [19.9]	628 [53.8]	676 [52.8]	1,810 [30.5]	30.3 (28.9; 31.7)
II	32 [1.2]	63 [5.4]	206 [20.0]	302 [5.2]	5.7 (5.1; 6.4)	19 [0.7]	44 [3.8]	189 [14.8]	252 [4.2]	3.8 (3.3; 4.3)
III	23 [0.9]	42 [3.6]	60 [5.8]	125 [2.2]	2.3 (1.9; 2.6)	24 [0.9]	26 [2.2]	43 [3.4]	93 [1.6]	1.5 (1.2; 1.9)
IV	5 [0.2]	3 [0.3]	11 [1.1]	19 [0.3]	0.4 (0.2; 0.5)	1 [0.0]	3 [0.3]	6 [0.5]	10 [0.2]	0.2 (0.1; 0.3)
X/NA	5 [0.2]	20 [1.7]	60 [5.8]	85 [1.5]	1.6 (1.2; 1.9)	7 [0.3]	15 [1.3]	60 [4.7]	82 [1.4]	1.3 (1.0; 1.5)

1.2.3. Melanoma incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-49	50-64	65+	All ages		15-49	50-64	65+	All ages	
I	240 [9.3]	518 [44.2]	694 [67.4]	1,452 [25.2]	26.2 (24.8; 27.5)	504 [19.8]	625 [53.6]	675 [52.7]	1,805 [30.4]	30.2 (28.8; 31.6)
II	30 [1.2]	61 [5.2]	192 [18.6]	284 [4.9]	5.4 (4.8; 6.0)	19 [0.7]	43 [3.7]	181 [14.1]	243 [4.1]	3.7 (3.2; 4.1)
III	24 [0.9]	41 [3.5]	66 [6.4]	131 [2.3]	2.4 (2.0; 2.8)	25 [1.0]	26 [2.2]	47 [3.7]	98 [1.7]	1.6 (1.3; 1.9)
IV	10 [0.4]	6 [0.5]	31 [3.0]	47 [0.8]	0.9 (0.6; 1.1)	3 [0.1]	7 [0.6]	23 [1.8]	33 [0.6]	0.5 (0.3; 0.7)
X/NA	2 [0.1]	20 [1.7]	49 [4.8]	71 [1.2]	1.3 (1.0; 1.6)	5 [0.2]	15 [1.3]	48 [3.7]	68 [1.1]	1.0 (0.8; 1.3)

1.2.4. Melanoma incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Sub-locations	Stage	Males N[CR]				ESR2013 (95%CI)	Females N[CR]				ESR2013 (95%CI)
		15-49	50-64	65+	All ages		15-49	50-64	65+	All ages	
Head	All	43 [1.7]	89 [7.6]	232 [22.5]	364 [6.3]	6.9 (6.2; 7.6)	32 [1.3]	60 [5.1]	179 [14.0]	271 [4.6]	4.2 (3.7; 4.7)
	I	30 [1.2]	76 [6.5]	123 [11.9]	229 [4.0]	4.2 (3.7; 4.8)	30 [1.2]	50 [4.3]	119 [9.3]	199 [3.4]	3.2 (2.7; 3.6)
	II	6 [0.2]	8 [0.7]	78 [7.6]	92 [1.6]	1.8 (1.5; 2.2)	1 [0.0]	7 [0.6]	46 [3.6]	54 [0.9]	0.8 (0.6; 1.0)
	III	5 [0.2]	3 [0.3]	14 [1.4]	22 [0.4]	0.4 (0.2; 0.6)	0 [0.0]	2 [0.2]	3 [0.2]	5 [0.1]	0.1 (0.0; 0.1)
	IV	2 [0.1]	1 [0.1]	11 [1.1]	14 [0.2]	0.3 (0.1; 0.4)	1 [0.0]	0 [0.0]	4 [0.3]	5 [0.1]	0.1 (0.0; 0.1)
	X/NA	0 [0.0]	1 [0.1]	6 [0.6]	7 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	1 [0.1]	7 [0.5]	8 [0.1]	0.1 (0.0; 0.2)
Trunk	All	131 [5.1]	305 [26.0]	411 [39.9]	847 [14.7]	15.2 (14.2; 16.2)	186 [7.3]	208 [17.8]	177 [13.8]	571 [9.6]	9.7 (8.9; 10.5)
	I	107 [4.2]	263 [22.4]	329 [32.0]	699 [12.1]	12.5 (11.6; 13.4)	169 [6.6]	181 [15.5]	130 [10.1]	480 [8.1]	8.2 (7.5; 8.9)
	II	10 [0.4]	21 [1.8]	49 [4.8]	80 [1.4]	1.5 (1.2; 1.8)	8 [0.3]	13 [1.1]	32 [2.5]	53 [0.9]	0.9 (0.6; 1.1)
	III	10 [0.4]	17 [1.4]	22 [2.1]	49 [0.9]	0.9 (0.6; 1.1)	9 [0.4]	11 [0.9]	12 [0.9]	32 [0.5]	0.5 (0.3; 0.7)
	IV	4 [0.2]	2 [0.2]	10 [1.0]	16 [0.3]	0.3 (0.1; 0.4)	0 [0.0]	3 [0.3]	3 [0.2]	6 [0.1]	0.1 (0.0; 0.2)
	X/NA	0 [0.0]	2 [0.2]	1 [0.1]	3 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
Upper limb	All	70 [2.7]	123 [10.5]	209 [20.3]	402 [7.0]	7.3 (6.6; 8.0)	136 [5.3]	176 [15.1]	266 [20.8]	578 [9.7]	9.5 (8.7; 10.3)
	I	60 [2.3]	99 [8.4]	156 [15.1]	315 [5.5]	5.7 (5.1; 6.3)	124 [4.9]	158 [13.5]	203 [15.8]	485 [8.2]	8.1 (7.4; 8.8)
	II	5 [0.2]	10 [0.9]	37 [3.6]	52 [0.9]	1.0 (0.7; 1.2)	6 [0.2]	11 [0.9]	54 [4.2]	71 [1.2]	1.0 (0.8; 1.3)
	III	4 [0.2]	12 [1.0]	11 [1.1]	27 [0.5]	0.5 (0.3; 0.7)	5 [0.2]	6 [0.5]	6 [0.5]	17 [0.3]	0.3 (0.1; 0.4)
	IV	1 [0.0]	2 [0.2]	4 [0.4]	7 [0.1]	0.1 (0.0; 0.2)	1 [0.0]	1 [0.1]	2 [0.2]	4 [0.1]	0.1 (0.0; 0.1)
	X/NA	0 [0.0]	0 [0.0]	1 [0.1]	1 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	1 [0.1]	1 [0.0]	0.0 (0.0; 0.0)
Lower limb	All	60 [2.3]	108 [9.2]	135 [13.1]	304 [5.3]	5.4 (4.8; 6.1)	195 [7.7]	255 [21.8]	310 [24.2]	761 [12.8]	12.6 (11.7; 13.5)
	I	43 [1.7]	78 [6.7]	83 [8.1]	204 [3.5]	3.6 (3.1; 4.1)	179 [7.0]	233 [20.0]	219 [17.1]	632 [10.6]	10.6 (9.8; 11.4)
	II	9 [0.4]	21 [1.8]	28 [2.7]	59 [1.0]	1.1 (0.8; 1.3)	4 [0.2]	11 [0.9]	48 [3.7]	63 [1.1]	1.0 (0.7; 1.2)

Sub-locations	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-49	50-64	65+	All ages		15-49	50-64	65+	All ages	
	III	5 [0.2]	9 [0.8]	18 [1.7]	32 [0.6]	0.6 (0.4; 0.8)	11 [0.4]	6 [0.5]	25 [2.0]	42 [0.7]	0.7 (0.5; 0.9)
	IV	3 [0.1]	0 [0.0]	5 [0.5]	8 [0.1]	0.2 (0.0; 0.3)	0 [0.0]	3 [0.3]	13 [1.0]	16 [0.3]	0.2 (0.1; 0.4)
	X/NA	0 [0.0]	0 [0.0]	1 [0.1]	1 [0.0]	0.0 (0.0; 0.1)	1 [0.0]	2 [0.2]	5 [0.4]	8 [0.1]	0.1 (0.0; 0.2)
Overlapping sites or unspecified	All	2 [0.1]	21 [1.8]	45 [4.4]	68 [1.2]	1.3 (1.0; 1.6)	7 [0.3]	17 [1.5]	42 [3.3]	66 [1.1]	1.0 (0.8; 1.3)
	I	0 [0.0]	2 [0.2]	3 [0.3]	5 [0.1]	0.1 (0.0; 0.2)	2 [0.1]	3 [0.3]	4 [0.3]	9 [0.2]	0.2 (0.1; 0.2)
	II	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	1 [0.1]	1 [0.1]	2 [0.0]	0.0 (0.0; 0.1)
	III	0 [0.0]	0 [0.0]	1 [0.1]	1 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	1 [0.1]	1 [0.1]	2 [0.0]	0.0 (0.0; 0.1)
	IV	0 [0.0]	1 [0.1]	1 [0.1]	2 [0.0]	0.0 (0.0; 0.1)	1 [0.0]	0 [0.0]	1 [0.1]	2 [0.0]	0.0 (0.0; 0.1)
	X/NA	2 [0.1]	17 [1.4]	40 [3.9]	59 [1.0]	1.1 (0.8; 1.4)	4 [0.2]	12 [1.0]	35 [2.7]	51 [0.9]	0.8 (0.6; 1.0)

1.2.5. Melanoma incidence by pT sub-categories, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

pT		Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-49	50-64	65+	All ages		15-49	50-64	65+	All ages	
1		219 [8.5]	444 [37.9]	593 [57.6]	1,256 [21.8]	22.6 (21.4; 23.9)	449 [17.6]	548 [47.0]	551 [43.0]	1,549 [26.1]	26.0 (24.7; 27.3)
	1a	188 [7.3]	376 [32.1]	522 [50.7]	1,086 [18.8]	19.6 (18.4; 20.7)	387 [15.2]	478 [41.0]	469 [36.6]	1,335 [22.5]	22.4 (21.2; 23.6)
	1b	31 [1.2]	65 [5.5]	68 [6.6]	164 [2.8]	2.9 (2.5; 3.4)	60 [2.4]	67 [5.7]	76 [5.9]	203 [3.4]	3.4 (2.9; 3.9)
2		39 [1.5]	97 [8.3]	141 [13.7]	277 [4.8]	5.0 (4.4; 5.6)	70 [2.8]	100 [8.6]	150 [11.7]	320 [5.4]	5.3 (4.7; 5.9)
	2a	33 [1.3]	90 [7.7]	117 [11.4]	240 [4.2]	4.3 (3.8; 4.9)	68 [2.7]	91 [7.8]	133 [10.4]	292 [4.9]	4.8 (4.3; 5.4)
	2b	6 [0.2]	7 [0.6]	20 [1.9]	33 [0.6]	0.6 (0.4; 0.8)	2 [0.1]	9 [0.8]	16 [1.2]	27 [0.5]	0.4 (0.3; 0.6)
3		23 [0.9]	50 [4.3]	108 [10.5]	182 [3.2]	3.4 (2.9; 3.9)	25 [1.0]	30 [2.6]	112 [8.7]	167 [2.8]	2.6 (2.2; 3.0)
	3a	16 [0.6]	26 [2.2]	56 [5.4]	99 [1.7]	1.8 (1.5; 2.2)	14 [0.6]	23 [2.0]	64 [5.0]	101 [1.7]	1.6 (1.3; 1.9)
	3b	7 [0.3]	24 [2.0]	50 [4.9]	81 [1.4]	1.5 (1.2; 1.8)	11 [0.4]	7 [0.6]	48 [3.7]	66 [1.1]	1.0 (0.8; 1.3)
4		18 [0.7]	34 [2.9]	129 [12.5]	181 [3.1]	3.4 (2.9; 4.0)	4 [0.2]	20 [1.7]	98 [7.6]	122 [2.1]	1.8 (1.5; 2.1)
	4a	8 [0.3]	13 [1.1]	43 [4.2]	64 [1.1]	1.2 (0.9; 1.5)	2 [0.1]	7 [0.6]	33 [2.6]	42 [0.7]	0.6 (0.4; 0.8)
	4b	10 [0.4]	21 [1.8]	84 [8.2]	115 [2.0]	2.2 (1.8; 2.6)	2 [0.1]	12 [1.0]	65 [5.1]	79 [1.3]	1.1 (0.9; 1.4)
X/NA		7 [0.3]	21 [1.8]	61 [5.9]	89 [1.5]	1.7 (1.3; 2.0)	8 [0.3]	18 [1.5]	63 [4.9]	89 [1.5]	1.4 (1.1; 1.7)

2.1. Melanoma incidence trends: by region

2.1.1. Melanoma incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	N	635	633	626	735	754	730	888	946	1,091	1,099	1,199	1,204	1,282	1,468	1,552	1,664	1,663	1,712	1,896	1,985		
	CR	12.5	12.4	12.2	14.2	14.4	13.9	16.7	17.6	20.2	20.2	21.9	21.9	23.2	26.4	27.7	29.6	29.4	30.2	33.2	34.5		
	ESR2013	14.2	14.3	13.9	15.7	16.5	15.7	18.6	19.9	22.2	22.3	24.1	24.1	25.2	28.3	29.8	31.5	31.2	31.7	35.1	36.1	5.5 (5.1; 5.9)	2004-2023
																						5.9 (5.3; 6.6)	2004-2016
																						4.7 (3.4; 5.9)	2017-2023
Brussels	N	60	63	57	71	73	80	84	98	91	96	106	83	101	98	116	94	101	102	140	119		
	CR	12.5	13.0	11.6	14.3	14.4	15.5	15.9	18.1	16.5	17.1	18.7	14.5	17.4	16.8	19.8	15.9	16.9	17.0	23.3	19.6		
	ESR2013	15.6	17.2	15.9	17.8	19.6	20.4	20.8	25.0	23.2	24.3	26.1	22.0	26.2	25.0	29.1	23.5	27.0	25.2	35.0	28.5	3.4 (2.7; 4.2)	2004-2023
																						5.9 (3.6; 8.3)	2004-2011
																						2.0 (0.8; 3.2)	2012-2023
Flanders	N	374	379	387	443	425	407	479	530	635	681	726	725	773	886	985	1,083	1,108	1,166	1,280	1,336		
	CR	12.6	12.7	12.9	14.7	14.0	13.3	15.5	17.0	20.3	21.6	22.9	22.8	24.1	27.5	30.4	33.2	33.8	35.4	38.6	39.9		
	ESR2013	13.9	13.8	13.9	15.8	15.4	14.4	16.8	18.2	21.3	22.8	24.0	23.5	24.9	28.1	30.9	33.5	34.0	35.4	38.5	39.6	6.0 (5.5; 6.5)	2004-2023
																						2.6 (0.0; 5.3)	2004-2008
																						6.9 (6.3; 7.6)	2009-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Wallonia	N	201	191	182	221	256	243	325	318	365	322	367	396	408	484	451	487	454	444	476	530		
	CR	12.3	11.6	11.0	13.3	15.3	14.4	19.1	18.5	21.2	18.6	21.1	22.6	23.2	27.4	25.5	27.4	25.5	24.9	26.6	29.4		
	ESR2013	14.2	14.6	13.4	15.0	18.1	17.1	21.7	21.9	23.8	20.9	24.1	26.1	25.8	30.0	28.3	29.9	27.4	26.7	28.9	31.5	4.4 (3.6; 5.2)	2004-2023
																						6.9 (4.9; 8.9)	2004-2012
																						4.8 (1.3; 8.3)	2013-2016
																						1.4 (-0.8; 3.7)	2017-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Melanoma incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	885	967	977	980	1,158	1,192	1,253	1,262	1,408	1,561	1,735	1,641	1,789	1,928	1,964	2,088	1,970	2,279	2,257	2,247		
	CR	16.7	18.1	18.2	18.1	21.3	21.7	22.7	22.6	25.0	27.6	30.6	28.8	31.2	33.5	34.0	36.0	33.8	39.0	38.4	37.9		
	ESR2013	16.8	18.4	18.4	18.2	21.3	21.6	22.7	22.6	25.1	27.9	30.5	28.8	31.0	33.3	33.8	35.7	33.3	38.3	37.6	37.0	4.4 (4.1; 4.8)	2004-2023
																						5.5 (4.9; 6.0)	2004-2017
																						2.3 (0.9; 3.6)	2018-2023
Brussels	**N**	84	82	89	94	96	113	105	109	113	105	115	98	140	119	125	120	112	138	127	129		
	CR	16.2	15.7	16.8	17.6	17.7	20.5	18.7	18.9	19.3	17.7	19.3	16.3	23.0	19.5	20.4	19.5	18.0	22.2	20.4	20.4		
	ESR2013	17.6	16.9	18.8	19.1	18.2	22.1	21.1	20.0	22.6	19.7	21.7	18.9	26.3	21.9	24.4	23.1	21.3	25.4	23.9	24.9	1.8 (1.1; 2.4)	2004-2023
Flanders	**N**	496	558	602	578	686	720	688	699	852	996	1,058	1,044	1,085	1,217	1,287	1,415	1,312	1,561	1,580	1,562		
	CR	16.3	18.2	19.5	18.6	22.0	22.9	21.7	21.9	26.5	30.8	32.6	32.0	33.1	36.9	38.9	42.5	39.2	46.5	46.7	45.6		
	ESR2013	16.2	18.2	19.4	18.4	21.6	22.5	21.4	21.5	26.0	30.6	32.0	31.3	32.2	36.0	37.8	41.3	37.7	44.8	44.7	43.5	5.7 (5.1; 6.3)	2004-2023
Wallonia	**N**	305	327	286	308	376	359	460	454	443	460	562	499	564	592	552	553	546	580	550	556		
	CR	17.5	18.7	16.3	17.4	21.1	20.1	25.6	25.1	24.3	25.2	30.6	27.1	30.6	32.0	29.8	29.8	29.3	31.1	29.4	29.6		
	ESR2013	18.0	19.2	16.6	17.7	21.6	20.3	25.9	25.2	24.7	25.4	30.7	27.5	30.7	32.1	29.9	29.8	29.1	30.7	28.9	29.1	2.9 (2.3; 3.5)	2004-2023
																						5.1 (4.1; 6.2)	2004-2016
																						-0.9 (-2.7; 0.9)	2017-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Melanoma incidence trends: by tumour stage

2.2.1. Melanoma incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards

Stage								Males								Females		
		2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period		2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	
I	N	1,186	1,198	1,253	1,382	1,452				1,637	1,560	1,800	1,763	1,805			
	CR	21.1	21.2	22.1	24.2	25.2				28.2	26.7	30.8	30.0	30.4			
	ESR2013	22.2	22.2	22.9	25.2	26.2	8.4 (7.6; 9.1)	2004-2023		28.4	26.8	30.8	29.8	30.2	6.7 (5.7; 7.6)	2004-2023	
							9.9 (8.9; 10.9)	2004-2018							8.0 (5.9; 10.1)	2004-2013	
							4.1 (1.2; 7.2)	2019-2023							10.1 (5.7; 14.7)	2014-2017	
															2.4 (-0.8; 5.8)	2018-2023	
II	N	261	247	235	290	284				277	226	294	276	243			
	CR	4.6	4.4	4.1	5.1	4.9				4.8	3.9	5.0	4.7	4.1			
	ESR2013	5.2	4.9	4.6	5.7	5.4	4.0 (3.3; 4.7)	2004-2023		4.4	3.5	4.5	4.3	3.7	3.1 (2.2; 4.1)	2004-2023	
															5.5 (4.0; 7.2)	2004-2016	
															-0.9 (-3.7; 1.9)	2017-2023	
III	N	111	119	127	115	131				93	113	110	124	98			
	CR	2.0	2.1	2.2	2.0	2.3				1.6	1.9	1.9	2.1	1.7			
	ESR2013	2.1	2.2	2.4	2.1	2.4	6.0 (5.0; 7.0)	2004-2023		1.6	1.9	1.8	2.0	1.6	5.6 (4.5; 6.8)	2004-2023	
															8.5 (5.7; 11.3)	2004-2013	
															3.1 (0.8; 5.5)	2014-2023	
IV	N	43	41	36	42	47				20	28	26	30	33			
	CR	0.8	0.7	0.6	0.7	0.8				0.3	0.5	0.4	0.5	0.6			
	ESR2013	0.8	0.8	0.7	0.8	0.9	2.7 (1.0; 4.4)	2004-2023		0.3	0.4	0.4	0.4	0.5	1.1 (-1.2; 3.5)	2004-2023	
X/NA	N	63	58	61	67	71				61	43	49	64	68			

Stage	Males							Females						
	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
CR	1.1	1.0	1.1	1.2	1.2			1.1	0.7	0.8	1.1	1.1		
ESR2013	1.2	1.1	1.2	1.3	1.3	-7.4 (-9.6; -5.0)	2004-2023	1.0	0.7	0.8	1.0	1.0	-10.4 (-13.3; -7.5)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Melanoma incidence trends: by age group

2.3.1. Melanoma incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
15-49	N	214	200	203	231	209	198	275	247	323	253	325	255	289	327	325	286	290	284	293	306		
	CR	8.5	7.9	8.0	9.1	8.2	7.8	10.8	9.6	12.6	9.9	12.7	10.0	11.4	12.9	12.8	11.3	11.4	11.2	11.5	11.9		
	ESR2013	8.5	7.9	8.0	9.1	8.2	7.8	10.8	9.6	12.6	9.9	12.8	10.1	11.5	13.1	13.0	11.5	11.7	11.5	11.9	12.4	2.3 (1.5; 3.2)	2004-2023
																						3.8 (2.4; 5.3)	2004-2016
																						-0.2 (-2.7; 2.4)	2017-2023
50-64	N	169	148	170	223	230	213	259	293	334	340	353	378	397	466	490	542	571	584	564	646		
	CR	18.7	16.0	18.0	23.0	23.1	20.9	24.9	27.6	31.2	31.4	32.2	34.0	35.3	41.0	42.8	47.1	49.3	50.1	48.2	55.1		
	ESR2013	18.8	16.3	18.3	23.0	23.2	21.0	25.1	27.7	31.3	31.4	32.3	34.2	35.5	41.2	42.9	47.0	49.1	49.8	48.0	54.7	6.4 (5.8; 7.0)	2004-2023
65+	N	249	284	250	278	314	317	353	405	432	506	521	571	596	673	736	835	801	843	1,036	1,032		
	CR	33.8	38.1	33.2	36.9	41.3	41.1	45.0	50.8	52.7	60.4	60.8	65.1	66.5	73.6	78.9	87.7	82.3	85.4	102.8	100.2		
	ESR2013	34.2	38.6	34.0	36.5	42.2	41.4	45.3	51.9	53.5	60.4	61.8	65.7	67.0	73.7	79.6	87.8	83.6	86.4	104.2	101.8	6.3 (5.9; 6.8)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.2. Melanoma incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
15-49	N	370	393	399	381	498	462	530	525	545	584	630	553	600	656	634	645	571	634	570	556		
	CR	15.0	15.9	16.1	15.3	20.0	18.5	21.2	20.9	21.6	23.2	25.1	22.1	24.0	26.3	25.4	25.9	22.8	25.4	22.7	21.9		
	ESR2013	14.9	15.8	16.1	15.3	20.0	18.5	21.2	21.0	21.8	23.4	25.3	22.3	24.4	26.6	25.9	26.2	23.2	25.9	23.2	22.4	2.6 (1.9; 3.3)	2004-2023
																						5.6 (3.5; 7.7)	2004-2011
																						4.2 (1.1; 7.4)	2012-2015
																						-0.7 (-2.3; 1.0)	2016-2023
50-64	N	213	251	235	280	288	331	322	305	380	443	518	510	544	570	606	692	660	760	742	716		
	CR	23.2	26.9	24.6	28.5	28.6	32.2	30.7	28.5	35.1	40.5	46.9	45.6	48.1	50.0	52.9	60.1	57.1	65.5	63.8	61.3		
	ESR2013	23.1	27.1	24.9	28.6	28.7	32.2	30.7	28.5	35.1	40.5	47.0	45.5	48.1	50.0	53.0	60.2	57.0	65.6	63.8	61.4	5.9 (5.2; 6.6)	2004-2023
65+	N	300	321	340	318	370	398	397	429	481	532	585	577	643	699	724	750	738	884	945	974		
	CR	28.7	30.5	32.2	30.1	35.0	37.3	36.9	39.5	43.5	47.5	51.5	50.1	55.1	59.2	60.5	61.8	60.0	71.2	74.9	76.0		
	ESR2013	28.6	30.3	31.8	29.4	34.3	36.0	36.5	38.5	43.3	48.4	50.8	50.7	54.6	59.0	60.9	62.3	60.2	70.7	75.5	76.6	5.5 (4.9; 6.1)	2004-2023
																						5.6 (5.2; 6.1)	2004-2022
																						3.2 (-7.8; 15.6)	2023-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3.1. Melanoma prevalence: by region

3.1.1. Melanoma prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	**N**	1,900	7,745	12,438	15,039	16,506	2,188	9,845	17,110	21,670	24,555
	CR	32.8	133.6	214.6	259	285	36.7	165.0	286.8	363	412
	ESR2013	34.1	138.7	223.0	269.8	296.1	35.8	161.0	279.2	353.2	399.7
Brussels	**N**	112	460	793	1,009	1,138	126	551	996	1,313	1,550
	CR	18.3	75.1	129.5	164.8	185.9	19.8	86.4	156.3	206.0	243.2
	ESR2013	26.5	112.2	194.5	246.2	277.5	24.2	102.9	185.4	245.6	291.4
Flanders	**N**	1,285	5,229	8,115	9,609	10,506	1,524	6,796	11,377	14,074	15,775
	CR	38.0	154.8	240.3	284.5	311.1	44.2	197.3	330.3	408.6	458.0
	ESR2013	37.6	152.6	236.8	280.3	306.3	42.1	188.4	313.9	387.3	433.3
Wallonia	**N**	503	2,056	3,530	4,421	4,862	538	2,498	4,737	6,283	7,230
	CR	27.8	113.7	195.3	244.6	269.0	28.5	132.5	251.3	333.4	383.6
	ESR2013	29.7	120.3	207.1	259.7	286.2	28.0	129.5	245.7	325.8	374.1

4.1. Melanoma survival: by region

4.1.1. Melanoma survival by region, sex and age group: number at risk and net survival probabilities, 2014-2023

			Net Survival Probability, 2014-2023			
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	**All**	34,367	98.4% (98.2%; 98.6%)	96.1% (95.7%; 96.5%)	95.4% (94.8%; 96.0%)	96.6% (95.0%; 98.2%)
Males						
Belgium	**All ages**	15,057	97.7% (97.3%; 98.1%)	94.9% (94.2%; 95.6%)	94.4% (93.5%; 95.4%)	97.0% (94.4%; 99.7%)
	15-49	2,903	99.1% (98.7%; 99.4%)	97.1% (96.4%; 97.8%)	95.7% (94.8%; 96.6%)	94.0% (92.6%; 95.5%)
	50-64	4,850	98.0% (97.6%; 98.5%)	95.1% (94.3%; 95.9%)	94.2% (93.2%; 95.2%)	94.4% (92.6%; 96.3%)
	65+	7,328	97.0% (96.3%; 97.7%)	93.9% (92.6%; 95.1%)	94.2% (92.3%; 96.1%)	100.6% (95.0%; 106.6%)
Brussels	**All ages**	1,007	97.2% (95.7%; 98.8%)	95.1% (92.5%; 97.8%)	92.8% (88.5%; 97.3%)	96.5% (86.7%; 107.3%)
	15-49	162	99.6% (98.4%; 100.8%)	95.1% (91.4%; 98.8%)	92.9% (88.4%; 97.6%)	91.2% (85.2%; 97.6%)
	50-64	294	96.9% (94.8%; 99.2%)	95.7% (92.7%; 98.7%)	93.4% (89.5%; 97.6%)	94.4% (88.5%; 100.6%)
	65+	551	96.7% (94.3%; 99.2%)	94.8% (90.4%; 99.4%)	92.3% (85.1%; 100.2%)	99.2% (82.4%; 119.5%)
Flanders	**All ages**	9,719	98.1% (97.6%; 98.5%)	95.6% (94.7%; 96.4%)	95.7% (94.5%; 96.9%)	100.5% (97.2%; 103.9%)
	15-49	1,752	99.1% (98.6%; 99.6%)	97.1% (96.2%; 98.0%)	96.1% (95.0%; 97.2%)	94.5% (92.7%; 96.4%)
	50-64	3,203	98.3% (97.8%; 98.9%)	95.5% (94.6%; 96.5%)	95.0% (93.8%; 96.2%)	96.4% (94.1%; 98.8%)
	65+	4,778	97.5% (96.7%; 98.4%)	95.0% (93.5%; 96.6%)	96.0% (93.7%; 98.4%)	106.6% (99.5%; 114.3%)
Wallonia	**All ages**	4,333	97.1% (96.4%; 97.8%)	93.3% (92.1%; 94.5%)	92.2% (90.5%; 93.9%)	90.0% (85.5%; 94.8%)

			Net Survival Probability, 2014-2023			
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	15-49	990	98.9% (98.2%; 99.6%)	97.3% (96.2%; 98.5%)	95.5% (94.1%; 97.1%)	93.7% (91.3%; 96.1%)
	50-64	1,354	97.7% (96.8%; 98.6%)	94.0% (92.5%; 95.5%)	92.5% (90.6%; 94.4%)	90.2% (86.9%; 93.6%)
	65+	1,999	95.7% (94.4%; 97.1%)	90.8% (88.5%; 93.2%)	90.3% (87.0%; 93.7%)	88.2% (78.3%; 99.3%)
Females						
Belgium	**All ages**	19,310	98.9% (98.6%; 99.1%)	97.0% (96.6%; 97.5%)	96.2% (95.5%; 96.9%)	96.4% (94.4%; 98.5%)
	15-49	5,894	99.7% (99.5%; 99.9%)	98.8% (98.4%; 99.1%)	98.2% (97.8%; 98.6%)	97.2% (96.5%; 97.9%)
	50-64	6,146	99.3% (99.1%; 99.6%)	98.2% (97.8%; 98.7%)	97.8% (97.2%; 98.4%)	97.9% (96.9%; 99.1%)
	65+	7,311	97.9% (97.3%; 98.5%)	94.7% (93.5%; 95.8%)	93.2% (91.4%; 95.0%)	94.7% (89.1%; 100.5%)
Brussels	**All ages**	1,183	98.4% (97.2%; 99.6%)	97.5% (95.4%; 99.6%)	96.7% (93.6%; 99.9%)	106.5% (98.1%; 115.6%)
	15-49	320	100.1% (100.1%; 100.1%)	99.0% (97.6%; 100.3%)	98.4% (96.7%; 100.1%)	97.3% (93.9%; 100.7%)
	50-64	330	99.2% (98.0%; 100.4%)	98.2% (96.3%; 100.2%)	97.6% (95.0%; 100.2%)	98.0% (93.8%; 102.3%)
	65+	536	96.9% (94.4%; 99.4%)	96.2% (91.9%; 100.7%)	95.2% (88.7%; 102.1%)	118.8% (99.5%; 141.8%)
Flanders	**All ages**	12,736	99.1% (98.8%; 99.4%)	97.6% (97.0%; 98.1%)	97.1% (96.3%; 98.0%)	97.1% (94.6%; 99.7%)
	15-49	3,672	99.6% (99.4%; 99.9%)	98.7% (98.3%; 99.1%)	98.1% (97.6%; 98.7%)	97.1% (96.2%; 98.0%)
	50-64	4,234	99.6% (99.3%; 99.8%)	98.4% (97.9%; 99.0%)	98.1% (97.4%; 98.8%)	98.7% (97.4%; 100.0%)
	65+	4,856	98.3% (97.6%; 99.0%)	95.9% (94.5%; 97.3%)	95.5% (93.4%; 97.6%)	95.9% (89.2%; 103.2%)
Wallonia	**All ages**	5,395	98.5% (98.0%; 99.0%)	95.7% (94.8%; 96.6%)	93.9% (92.6%; 95.3%)	92.6% (89.0%; 96.3%)
	15-49	1,902	99.8% (99.5%; 100.0%)	98.8% (98.2%; 99.3%)	98.3% (97.6%; 99.0%)	97.3% (96.0%; 98.7%)
	50-64	1,583	98.7% (98.1%; 99.4%)	97.6% (96.7%; 98.6%)	96.9% (95.7%; 98.1%)	96.1% (93.9%; 98.4%)
	65+	1,922	97.1% (95.9%; 98.4%)	91.1% (88.7%; 93.5%)	87.0% (83.5%; 90.8%)	84.7% (74.6%; 96.1%)

4.2. Melanoma survival: by tumour stage

4.2.1. Melanoma survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2014-2023

cStage	N at risk	Net Survival Probability, 2014-2023					
		1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	34,367	98.4% (98.2%; 98.6%)	97.0% (96.7%; 97.3%)	96.1% (95.7%; 96.5%)	95.5% (95.0%; 96.0%)	95.4% (94.8%; 96.0%)	96.6% (95.0%; 98.2%)
Males							
Total	15,057	97.7% (97.3%; 98.1%)	95.9% (95.4%; 96.4%)	94.9% (94.2%; 95.6%)	94.5% (93.7%; 95.3%)	94.4% (93.5%; 95.4%)	97.0% (94.4%; 99.7%)
I	10,997	101.0% (100.7%; 101.2%)	101.4% (101.0%; 101.8%)	102.2% (101.6%; 102.7%)	103.1% (102.5%; 103.8%)	103.8% (102.9%; 104.7%)	109.0% (106.1%; 112.0%)
II	2,944	96.3% (95.2%; 97.3%)	88.8% (87.2%; 90.5%)	82.9% (80.9%; 85.0%)	78.9% (76.5%; 81.4%)	76.8% (74.0%; 79.7%)	70.3% (64.3%; 76.9%)
III	250	85.3% (80.6%; 90.4%)	75.7% (69.8%; 82.1%)	72.0% (65.5%; 79.2%)	68.5% (61.2%; 76.6%)	66.0% (57.9%; 75.3%)	50.7% (38.0%; 67.6%)
IV	277	62.3% (56.5%; 68.6%)	49.5% (43.4%; 56.3%)	38.5% (32.3%; 45.9%)	34.8% (28.5%; 42.6%)	31.8% (25.2%; 40.0%)	21.9% (13.8%; 34.9%)
X/NA	728	71.9% (68.5%; 75.5%)	64.4% (60.6%; 68.5%)	60.8% (56.7%; 65.3%)	57.6% (53.1%; 62.5%)	57.8% (52.9%; 63.1%)	63.6% (51.8%; 77.9%)
Females							
Total	19,310	98.9% (98.6%; 99.1%)	97.9% (97.5%; 98.2%)	97.0% (96.6%; 97.5%)	96.3% (95.7%; 96.9%)	96.2% (95.5%; 96.9%)	96.4% (94.4%; 98.5%)
I	15,251	100.7% (100.5%; 100.8%)	101.1% (100.9%; 101.3%)	101.4% (101.1%; 101.8%)	101.8% (101.3%; 102.2%)	102.2% (101.6%; 102.7%)	104.4% (102.3%; 106.4%)
II	3,056	97.5% (96.5%; 98.4%)	91.7% (90.2%; 93.2%)	87.2% (85.3%; 89.2%)	82.5% (80.1%; 84.9%)	80.3% (77.6%; 83.1%)	73.3% (67.2%; 79.9%)
III	243	88.9% (84.6%; 93.6%)	75.9% (70.0%; 82.2%)	70.0% (63.5%; 77.3%)	64.7% (57.4%; 72.9%)	63.8% (56.2%; 72.5%)	50.8% (36.1%; 71.4%)
IV	194	67.6% (61.0%; 75.0%)	49.7% (42.4%; 58.1%)	42.0% (34.5%; 51.0%)	34.1% (26.2%; 44.5%)	35.0% (26.9%; 45.6%)	28.3% (18.9%; 42.3%)
X/NA	673	77.5% (74.2%; 80.9%)	72.4% (68.7%; 76.3%)	67.1% (62.9%; 71.5%)	64.2% (59.7%; 68.9%)	62.5% (57.7%; 67.7%)	60.1% (49.8%; 72.5%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

4.2.2. Melanoma survival by pathological stage (pStage) and sex: number at risk and net survival probabilities, 2014-2023

| pStage | N at risk | Net Survival Probability, 2014-2023 | | | | | |
		1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	34,367	98.4% (98.2%; 98.6%)	97.0% (96.7%; 97.3%)	96.1% (95.7%; 96.5%)	95.5% (95.0%; 96.0%)	95.4% (94.8%; 96.0%)	96.6% (95.0%; 98.2%)
Males							
Total	15,057	97.7% (97.3%; 98.1%)	95.9% (95.4%; 96.4%)	94.9% (94.2%; 95.6%)	94.5% (93.7%; 95.3%)	94.4% (93.5%; 95.4%)	97.0% (94.4%; 99.7%)
I	10,755	101.0% (100.7%; 101.2%)	101.5% (101.1%; 101.9%)	102.2% (101.7%; 102.8%)	103.3% (102.6%; 104.0%)	104.0% (103.1%; 104.9%)	109.3% (106.4%; 112.4%)
II	2,431	95.1% (93.9%; 96.4%)	89.4% (87.6%; 91.3%)	83.6% (81.3%; 86.0%)	80.5% (77.8%; 83.4%)	78.9% (75.7%; 82.2%)	73.5% (66.3%; 81.4%)
III	1,079	94.9% (93.3%; 96.5%)	85.1% (82.6%; 87.7%)	79.3% (76.4%; 82.4%)	73.4% (70.0%; 77.0%)	70.2% (66.5%; 74.1%)	62.7% (56.6%; 69.5%)
IV	155	70.6% (63.3%; 78.6%)	50.6% (42.7%; 59.9%)	45.1% (37.0%; 55.0%)	42.2% (33.9%; 52.5%)	37.7% (29.2%; 48.7%)	35.7% (24.6%; 51.8%)
X/NA	791	70.1% (66.8%; 73.6%)	62.1% (58.4%; 66.0%)	58.1% (54.2%; 62.4%)	54.8% (50.4%; 59.5%)	54.8% (50.1%; 59.9%)	57.9% (46.9%; 71.5%)
Females							
Total	19,310	98.9% (98.6%; 99.1%)	97.9% (97.5%; 98.2%)	97.0% (96.6%; 97.5%)	96.3% (95.7%; 96.9%)	96.2% (95.5%; 96.9%)	96.4% (94.4%; 98.5%)
I	15,020	100.6% (100.5%; 100.8%)	101.1% (100.9%; 101.4%)	101.5% (101.2%; 101.8%)	101.8% (101.4%; 102.3%)	102.3% (101.7%; 102.9%)	104.6% (102.5%; 106.6%)
II	2,599	97.1% (96.0%; 98.2%)	91.4% (89.7%; 93.1%)	87.2% (85.0%; 89.4%)	82.7% (80.1%; 85.4%)	80.7% (77.6%; 83.9%)	73.7% (67.1%; 81.0%)
III	970	96.6% (95.1%; 98.0%)	88.7% (86.3%; 91.1%)	83.1% (80.3%; 86.1%)	78.2% (74.8%; 81.7%)	76.2% (72.5%; 80.0%)	70.2% (62.4%; 79.1%)
IV	102	74.9% (66.6%; 84.3%)	63.9% (54.4%; 74.9%)	57.7% (47.6%; 70.1%)	46.1% (34.5%; 61.6%)	43.1% (31.4%; 59.3%)	42.4% (26.9%; 66.8%)
X/NA	730	76.0% (72.8%; 79.4%)	70.0% (66.3%; 73.9%)	64.4% (60.4%; 68.7%)	61.5% (57.2%; 66.2%)	59.8% (55.2%; 64.8%)	56.9% (47.3%; 68.6%)

4.2.3. Melanoma survival by stage and sex: number at risk and net survival probabilities, 2014-2023

| Stage | N at risk | Net Survival Probability, 2014-2023 | | | | | |
		1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	34,367	98.4% (98.2%; 98.6%)	97.0% (96.7%; 97.3%)	96.1% (95.7%; 96.5%)	95.5% (95.0%; 96.0%)	95.4% (94.8%; 96.0%)	96.6% (95.0%; 98.2%)
Males							
Total	15,057	97.7% (97.3%; 98.1%)	95.9% (95.4%; 96.4%)	94.9% (94.2%; 95.6%)	94.5% (93.7%; 95.3%)	94.4% (93.5%; 95.4%)	97.0% (94.4%; 99.7%)
I	10,743	101.0% (100.8%; 101.2%)	101.5% (101.1%; 101.9%)	102.3% (101.8%; 102.9%)	103.4% (102.7%; 104.1%)	104.1% (103.2%; 105.0%)	109.4% (106.4%; 112.4%)
II	2,349	96.5% (95.3%; 97.8%)	91.1% (89.3%; 93.0%)	85.4% (83.1%; 87.8%)	82.2% (79.4%; 85.1%)	80.6% (77.4%; 84.0%)	75.2% (67.8%; 83.3%)
III	1,067	95.0% (93.4%; 96.6%)	85.0% (82.5%; 87.6%)	80.0% (77.0%; 83.0%)	74.0% (70.6%; 77.6%)	71.1% (67.4%; 75.0%)	63.7% (57.5%; 70.5%)
IV	349	65.4% (60.3%; 70.9%)	50.3% (44.8%; 56.4%)	40.5% (34.9%; 47.0%)	38.1% (32.3%; 45.0%)	33.8% (27.7%; 41.1%)	26.6% (18.5%; 38.4%)
X/NA	705	71.1% (67.6%; 74.8%)	63.4% (59.5%; 67.6%)	59.8% (55.6%; 64.3%)	56.5% (51.9%; 61.6%)	56.6% (51.6%; 62.0%)	61.5% (49.7%; 76.2%)
Females							
Total	19,310	98.9% (98.6%; 99.1%)	97.9% (97.5%; 98.2%)	97.0% (96.6%; 97.5%)	96.3% (95.7%; 96.9%)	96.2% (95.5%; 96.9%)	96.4% (94.4%; 98.5%)
I	15,006	100.7% (100.5%; 100.8%)	101.2% (101.0%; 101.4%)	101.5% (101.2%; 101.9%)	101.9% (101.5%; 102.3%)	102.4% (101.8%; 102.9%)	104.6% (102.6%; 106.7%)
II	2,544	97.6% (96.6%; 98.7%)	92.4% (90.7%; 94.1%)	88.3% (86.2%; 90.5%)	84.1% (81.5%; 86.8%)	82.0% (78.9%; 85.2%)	75.0% (68.2%; 82.5%)
III	974	96.2% (94.7%; 97.8%)	88.4% (86.0%; 90.9%)	83.2% (80.3%; 86.2%)	78.2% (74.8%; 81.7%)	76.0% (72.3%; 79.8%)	70.1% (62.2%; 79.0%)
IV	236	70.5% (64.5%; 77.0%)	54.1% (47.5%; 61.7%)	45.8% (38.9%; 54.0%)	36.4% (28.8%; 46.0%)	35.6% (27.8%; 45.5%)	30.8% (20.9%; 45.6%)
X/NA	662	77.2% (73.9%; 80.7%)	72.0% (68.3%; 76.0%)	66.5% (62.4%; 71.0%)	63.5% (59.0%; 68.4%)	61.9% (57.1%; 67.1%)	59.4% (49.2%; 71.7%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

Belgian Cancer Registry

5.1. Melanoma survival trends: by tumour stage

5.1.1. Melanoma survival trends by stage and sex: number at risk and net survival probabilities, 2004-2023

		Males				Females			
		Net Survival Probability				Net Survival Probability			
Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2008	**All**	3,299	94.9% (94.0%; 95.8%)	87.2% (85.6%; 88.7%)	83.7% (81.8%; 85.7%)	4,876	96.5% (95.8%; 97.1%)	91.9% (90.9%; 93.0%)	89.5% (88.2%; 90.9%)
	I	1,622	100.3% (99.6%; 101.0%)	100.4% (99.1%; 101.7%)	99.8% (97.9%; 101.8%)	2,827	100.1% (99.7%; 100.5%)	99.9% (99.1%; 100.7%)	99.6% (98.6%; 100.7%)
	II	599	97.1% (95.0%; 99.3%)	78.7% (74.3%; 83.3%)	71.5% (66.1%; 77.4%)	678	95.7% (93.6%; 97.9%)	79.8% (75.8%; 84.1%)	72.2% (67.1%; 77.6%)
	III	220	84.7% (79.8%; 90.0%)	61.6% (55.0%; 69.0%)	54.4% (47.4%; 62.4%)	215	93.0% (89.3%; 96.9%)	79.0% (73.1%; 85.4%)	67.3% (60.4%; 74.9%)
	IV	116	62.8% (54.4%; 72.6%)	29.7% (22.1%; 39.9%)	24.8% (17.6%; 35.0%)	107	61.1% (52.3%; 71.3%)	41.1% (32.3%; 52.4%)	29.9% (21.9%; 40.9%)
	X/NA	759	89.3% (86.9%; 91.9%)	81.2% (77.8%; 84.8%)	75.7% (71.6%; 80.1%)	1,075	91.7% (89.8%; 93.6%)	86.1% (83.5%; 88.8%)	83.9% (80.8%; 87.2%)
2009-2013	**All**	4,658	95.1% (94.4%; 95.9%)	89.3% (88.0%; 90.5%)	87.4% (85.9%; 89.0%)	6,574	97.9% (97.5%; 98.4%)	94.7% (93.9%; 95.6%)	93.3% (92.2%; 94.3%)
	I	2,592	100.4% (99.9%; 100.9%)	101.1% (100.1%; 102.2%)	102.2% (100.6%; 103.7%)	4,083	100.4% (100.1%; 100.7%)	100.7% (100.1%; 101.3%)	100.9% (100.0%; 101.8%)
	II	771	95.1% (93.0%; 97.3%)	79.1% (75.2%; 83.1%)	71.4% (66.7%; 76.4%)	919	97.7% (96.1%; 99.4%)	85.7% (82.5%; 89.2%)	79.9% (75.8%; 84.3%)
	III	322	91.8% (88.4%; 95.3%)	67.8% (62.3%; 73.9%)	59.5% (53.4%; 66.4%)	321	94.4% (91.6%; 97.3%)	80.2% (75.5%; 85.3%)	70.3% (64.7%; 76.2%)
	IV	131	48.2% (40.1%; 57.8%)	24.1% (17.4%; 33.4%)	19.6% (13.4%; 28.8%)	89	65.8% (56.4%; 76.8%)	40.4% (30.9%; 52.8%)	31.5% (22.4%; 44.3%)
	X/NA	872	87.6% (85.1%; 90.1%)	80.4% (77.1%; 83.8%)	78.4% (74.6%; 82.4%)	1,183	92.9% (91.2%; 94.6%)	88.9% (86.6%; 91.3%)	87.8% (85.0%; 90.8%)
2014-2018	**All**	6,552	97.0% (96.4%; 97.6%)	93.6% (92.6%; 94.5%)	92.6% (91.3%; 94.0%)	8,907	98.9% (98.6%; 99.3%)	97.1% (96.4%; 97.8%)	96.0% (95.1%; 96.9%)
	I	4,555	101.0% (100.6%; 101.3%)	102.2% (101.4%; 102.9%)	103.6% (102.4%; 104.8%)	6,776	100.7% (100.5%; 100.9%)	101.5% (101.0%; 101.9%)	102.1% (101.4%; 102.8%)
	II	1,047	95.3% (93.5%; 97.2%)	83.5% (80.2%; 86.9%)	77.4% (73.1%; 81.9%)	1,246	97.0% (95.5%; 98.6%)	89.2% (86.3%; 92.1%)	82.6% (78.7%; 86.8%)

Period	Stage	Males N at risk	Males 1-y (95%CI)	Males 3-y (95%CI)	Males 5-y (95%CI)	Females N at risk	Females 1-y (95%CI)	Females 3-y (95%CI)	Females 5-y (95%CI)
			Net Survival Probability				**Net Survival Probability**		
	III	466	92.6% (89.9%; 95.4%)	76.9% (72.6%; 81.5%)	68.3% (63.3%; 73.7%)	439	95.7% (93.4%; 98.0%)	82.7% (78.6%; 87.0%)	75.2% (70.4%; 80.4%)
	IV	143	62.7% (54.9%; 71.6%)	34.0% (26.5%; 43.6%)	29.1% (21.6%; 39.3%)	99	74.3% (65.7%; 84.0%)	43.0% (33.4%; 55.2%)	36.5% (26.5%; 50.4%)
	X/NA	387	72.0% (67.4%; 77.0%)	59.0% (53.6%; 65.1%)	55.7% (49.5%; 62.7%)	381	83.6% (79.6%; 87.7%)	74.5% (69.4%; 80.0%)	68.7% (62.7%; 75.2%)
2019-2023	All	8,637	98.3% (97.8%; 98.8%)	96.0% (95.1%; 96.9%)	96.6% (95.2%; 98.0%)	10,566	98.9% (98.5%; 99.2%)	97.0% (96.3%; 97.7%)	96.5% (95.4%; 97.6%)
	I	6,278	101.0% (100.7%; 101.4%)	102.4% (101.7%; 103.2%)	105.0% (103.7%; 106.3%)	8,350	100.7% (100.5%; 100.8%)	101.6% (101.1%; 102.1%)	102.5% (101.6%; 103.5%)
	II	1,306	97.4% (95.8%; 99.0%)	86.9% (83.6%; 90.3%)	85.2% (80.4%; 90.3%)	1,306	98.1% (96.7%; 99.6%)	87.0% (83.8%; 90.4%)	81.2% (76.3%; 86.4%)
	III	602	96.9% (94.9%; 98.8%)	82.6% (78.7%; 86.8%)	72.6% (66.8%; 78.9%)	536	96.7% (94.7%; 98.7%)	83.7% (79.6%; 88.0%)	77.6% (72.0%; 83.6%)
	IV	206	67.2% (60.7%; 74.5%)	46.3% (38.7%; 55.4%)	37.1% (28.2%; 48.8%)	137	67.7% (59.8%; 76.6%)	49.3% (40.0%; 60.6%)	32.3% (21.1%; 49.3%)
	X/NA	318	69.9% (64.7%; 75.6%)	61.1% (54.8%; 68.1%)	58.2% (50.3%; 67.3%)	281	68.6% (63.1%; 74.6%)	55.1% (48.5%; 62.6%)	53.3% (45.6%; 62.3%)

6.1. Melanoma mortality: by region

6.1.1. Melanoma mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Males																						
Belgium	0	0	0	0	0	1	1	2	3	4	11	16	10	20	27	24	21	23	9	2	174	3.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.5]	[0.8]	[1.1]	[2.8]	[4.0]	[2.8]	[6.5]	[10.2]	[13.8]	[16.1]	[29.6]	[32.1]	[36.7]	[3.1]	(2.9; 3.9)
Brussels	0	0	0	0	0	0	0	0	0	1	0	2	1	1	2	2	0	1	1	0	11	3.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.3]	[0.0]	[5.9]	[3.7]	[4.8]	[12.0]	[17.4]	[0.0]	[19.8]	[46.0]	[0.0]	[1.8]	(1.2; 4.8)
Flanders	0	0	0	0	0	1	1	2	2	3	9	8	8	17	15	15	17	17	4	2	121	3.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.5]	[1.0]	[0.9]	[1.4]	[3.8]	[3.3]	[3.6]	[9.1]	[9.3]	[13.1]	[19.7]	[32.9]	[21.8]	[55.9]	[3.7]	(3.1; 4.4)
Wallonia	0	0	0	0	0	0	0	0	1	0	2	6	1	2	10	7	4	5	4	0	42	2.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[1.6]	[4.8]	[0.9]	[2.0]	[11.6]	[14.4]	[11.1]	[23.9]	[52.8]	[0.0]	[2.4]	(2.0; 3.8)
Females																						
Belgium	0	0	0	0	0	0	1	4	5	7	10	4	12	20	16	28	24	18	11	4	164	2.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[1.1]	[1.3]	[1.9]	[2.6]	[1.0]	[3.2]	[6.1]	[5.4]	[13.1]	[13.0]	[13.3]	[16.6]	[20.8]	[2.8]	(2.2; 3.0)
Brussels	0	0	0	0	0	0	0	0	0	0	0	1	1	1	2	2	0	0	2	0	9	1.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[3.0]	[3.4]	[4.1]	[9.3]	[12.3]	[0.0]	[0.0]	[34.8]	[0.0]	[1.4]	(0.6; 3.1)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	0	0	0	0	0	0	1	3	2	6	5	3	6	14	9	19	16	15	6	3	108	2.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.4]	[0.9]	[2.9]	[2.2]	[1.3]	[2.7]	[7.3]	[5.2]	[14.3]	[13.8]	[17.6]	[15.0]	[26.7]	[3.2]	(2.3; 3.3)
Wallonia	0	0	0	0	0	0	0	1	3	1	5	0	5	5	5	7	8	3	3	1	47	2.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[2.6]	[0.8]	[4.0]	[0.0]	[4.1]	[4.6]	[5.0]	[11.0]	[14.5]	[7.5]	[14.7]	[16.6]	[2.5]	(1.7; 3.1)

Belgian Cancer Registry

7.1. Melanoma mortality trends: by region

7.1.1. Melanoma mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	**N**	130	149	145	151	167	163	167	179	155	196	171	169	184	175	189	153	173	174		
	CR	2.6	2.9	2.8	2.9	3.2	3.1	3.1	3.3	2.9	3.6	3.1	3.1	3.3	3.1	3.4	2.7	3.1	3.1		
	ESR2013	3.2	3.7	3.4	3.4	4.0	3.7	3.9	4.1	3.5	4.3	3.6	3.5	3.8	3.5	3.8	3.1	3.3	3.4	-0.3 (-0.9; 0.4)	2004-2021
																				1.7 (0.2; 3.1)	2004-2013
																				-2.4 (-3.9; -0.8)	2014-2021
Brussels	**N**	9	10	11	13	10	7	12	11	11	7	11	8	11	13	13	11	9	11		
	CR	1.9	2.1	2.2	2.6	2.0	1.4	2.3	2.0	2.0	1.2	1.9	1.4	1.9	2.2	2.2	1.9	1.5	1.8		
	ESR2013	2.2	2.6	3.3	3.6	2.4	1.7	3.3	3.4	3.3	2.0	3.0	2.0	3.5	3.5	3.6	3.1	2.4	3.0	0.9 (-1.4; 3.2)	2004-2021
Flanders	**N**	72	101	104	86	112	108	111	118	100	132	107	119	117	119	128	99	103	121		
	CR	2.4	3.4	3.5	2.9	3.7	3.5	3.6	3.8	3.2	4.2	3.4	3.7	3.7	3.7	3.9	3.0	3.1	3.7		
	ESR2013	3.0	4.1	4.0	3.2	4.3	4.2	4.2	4.3	3.6	4.7	3.6	4.0	3.8	3.8	4.1	3.2	3.2	3.7	-0.3 (-1.4; 0.8)	2004-2021
																				2.0 (-0.2; 4.4)	2004-2013
																				-2.8 (-5.3; -0.3)	2014-2021
Wallonia	**N**	49	38	30	52	45	48	44	50	44	57	53	42	56	43	48	43	61	42		
	CR	3.0	2.3	1.8	3.1	2.7	2.8	2.6	2.9	2.6	3.3	3.0	2.4	3.2	2.4	2.7	2.4	3.4	2.4		

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
ESR2013	3.9	3.3	2.5	3.8	3.7	3.4	3.5	3.8	3.4	4.2	3.7	3.0	3.8	2.9	3.2	2.8	4.0	2.9	-0.4 (-1.8; 1.0)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Melanoma mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	**N**	146	131	122	151	150	154	149	173	136	185	185	157	154	150	166	152	149	164		
	CR	2.7	2.5	2.3	2.8	2.8	2.8	2.7	3.1	2.4	3.3	3.3	2.8	2.7	2.6	2.9	2.6	2.6	2.8		
	ESR2013	2.7	2.5	2.3	2.8	2.7	2.7	2.6	3.0	2.3	3.2	3.1	2.6	2.5	2.4	2.6	2.4	2.3	2.6	-0.4 (-1.4; 0.6)	2004-2021
Brussels	**N**	18	8	12	12	11	11	11	15	13	18	16	10	10	11	17	8	7	9		
	CR	3.5	1.5	2.3	2.2	2.0	2.0	2.0	2.6	2.2	3.0	2.7	1.7	1.6	1.8	2.8	1.3	1.1	1.4		
	ESR2013	3.7	1.8	2.6	2.7	2.2	2.3	2.1	3.1	2.4	3.3	3.0	1.8	1.9	2.0	3.0	1.3	1.4	1.9	-2.6 (-5.0; -0.2)	2004-2021
Flanders	**N**	95	77	71	102	95	108	89	110	86	121	128	103	101	105	99	116	106	108		
	CR	3.1	2.5	2.3	3.3	3.0	3.4	2.8	3.4	2.7	3.7	3.9	3.2	3.1	3.2	3.0	3.5	3.2	3.2		
	ESR2013	3.1	2.6	2.3	3.2	2.9	3.2	2.7	3.3	2.4	3.5	3.6	2.9	2.8	2.9	2.6	3.1	2.7	2.8	0.0 (-1.2; 1.3)	2004-2021
Wallonia	**N**	33	46	39	37	44	35	49	48	37	46	41	44	43	34	50	28	36	47		
	CR	1.9	2.6	2.2	2.1	2.5	2.0	2.7	2.7	2.0	2.5	2.2	2.4	2.3	1.8	2.7	1.5	1.9	2.5		
	ESR2013	1.9	2.7	2.3	2.1	2.5	2.0	2.6	2.6	2.0	2.4	2.0	2.3	2.2	1.8	2.4	1.4	1.9	2.4	-1.0 (-2.6; 0.6)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2023, Belgian Cancer Registry (BCR), 2025